Thus, anti-CTLA-4 and anti-CD20 combined treatment is a possible new clinical strategy in overcoming adaptive resistance and preventing relapse of B-cell lymphoma. Here, CTLA4 is linked to B-cell non-Hodgkin lymphoma.